Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma